WHO joins agencies in beefing up inspections of API facilities

The World Health Organization (WHO) is joining an effort to extend the reach of regulatory inspections of API facilities and reduce duplication by sharing resources, InPharm reports. The effort was started by the US, Europe and Australia, allowing each to rely on inspections by the others to better use existing resources. The FDA, EMA and the Australian Therapeutic Goods Administration (TGA) can accept a report, ask regulators of one of the participants to expand an inspection or they can hold joint inspections. A recent report on the effort noted the WHO has joined through its Prequalification of Medicines program and that other entities agreeing to the requirements also may be allowed to participate. Story | Report

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.